Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Decreased by Tobam

Tobam lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 57.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 31,268 shares of the company’s stock after selling 41,978 shares during the quarter. Neurocrine Biosciences comprises 1.3% of Tobam’s holdings, making the stock its 26th biggest position. Tobam’s holdings in Neurocrine Biosciences were worth $4,268,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of NBIX. Sumitomo Mitsui Trust Group Inc. raised its holdings in Neurocrine Biosciences by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 232,857 shares of the company’s stock worth $31,785,000 after purchasing an additional 916 shares in the last quarter. Oakworth Capital Inc. bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth $379,000. Choreo LLC lifted its holdings in shares of Neurocrine Biosciences by 44.3% in the fourth quarter. Choreo LLC now owns 3,765 shares of the company’s stock valued at $516,000 after buying an additional 1,156 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Neurocrine Biosciences by 21.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,358 shares of the company’s stock worth $2,251,000 after acquiring an additional 2,925 shares during the period. Finally, Retirement Systems of Alabama raised its position in Neurocrine Biosciences by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 123,107 shares of the company’s stock worth $16,804,000 after acquiring an additional 446 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on NBIX shares. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. BMO Capital Markets reduced their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Raymond James reissued an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Morgan Stanley upped their price objective on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $166.85.

Neurocrine Biosciences Trading Down 0.5 %

Shares of NBIX stock opened at $150.51 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The firm’s fifty day simple moving average is $138.41 and its 200 day simple moving average is $131.64. The firm has a market capitalization of $15.24 billion, a P/E ratio of 40.35 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 17.21% and a return on equity of 15.68%. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 623 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $149.29, for a total value of $93,007.67. Following the completion of the transaction, the insider now directly owns 3,442 shares in the company, valued at approximately $513,856.18. This represents a 15.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. This represents a 13.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 222,693 shares of company stock valued at $32,718,279 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.